Horizon Discovery Wins Drug Screening Contract

Horizon Discovery Group’s CombinatoRx division has entered an agreement with a top ten pharma company to profile a lead oncology asset. Horizon CombinatoRx will receive approximately $450,000 for work to be completed within a six-month period.   
 
Horizon will support proof-of-concept, monotherapy screening, and combination screening for the lead asset, providing access to its cHTS platform and Chalice analytics software, which enable the screening and analysis of thousands of complementary drug combinations. Horizon Discovery recently completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc.
 
Dr. Darrin Disley, chief executive officer of Horizon Discovery Group, said, “We are delighted that Horizon CombinatoRx continues to gain traction in the market, following the acquisition earlier this year.  This latest contract with a top ten pharma in the oncology space continues to demonstrate the potential of this business and the value Horizon CombinatoRx can offer to support key drug discovery and development programs in cancer.”